CapsoVision (CV) Income from Continuing Operations (2024 - 2025)
CapsoVision (CV) reported Income from Continuing Operations of 7394000.0 for Q4 2025, down 59.39% on a YoY basis from 18206351.38 in Q4 2024, and up 6.65% sequentially from 7921000.0 in Q3 2025.
CapsoVision (CV) Income from Continuing Operations (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of Income from Continuing Operations data on file, last reported at 7394000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 59.39% year-over-year to 7394000.0; the trailing twelve-month figure through Dec 2025 stood at 24579000.0 (changed N/A YoY), and the FY2025 full-year result was 25315000.0, down 27.22% from the prior year.
- Income from Continuing Operations grew to 7394000.0 in Q4 2025, from 7921000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4625000.0 in Q2 2025 to a low of 7921000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn | -7.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.39 Mn |
| Sep 30, 2025 | -7.92 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Dec 31, 2024 | -4.64 Mn |
| Sep 30, 2024 | -5.79 Mn |
| Jun 30, 2024 | -5.27 Mn |